In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 251 to 300 of 395

TitleTypeExpected publication date
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]Technology appraisal guidanceTBC
Orforglipron for managing overweight and obesity ID6516Technology appraisal guidanceTBC
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]Technology appraisal guidance
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]Technology appraisal guidanceTBC
OsteoporosisQuality standardTBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)NICE guidelineTBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]Technology appraisal guidanceTBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]Technology appraisal guidanceTBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Technology appraisal guidanceTBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]Technology appraisal guidance
Peezy Midstream for urine collection (MT446)Medical technologies guidanceTBC
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594Technology appraisal guidanceTBC
Pegcetacoplan for treating geographic atrophy [ID4041]Technology appraisal guidanceTBC
Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]Technology appraisal guidance
Pegzilarginase for treating arginase-1 deficiency [ID4029]Highly specialised technology
Pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck cancer [ID6477]Technology appraisal guidance
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Technology appraisal guidance
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473Technology appraisal guidanceTBC
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363Technology appraisal guidanceTBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]Technology appraisal guidanceTBC
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]Technology appraisal guidanceTBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]Technology appraisal guidanceTBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]Technology appraisal guidanceTBC
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]Technology appraisal guidanceTBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]Technology appraisal guidanceTBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]Technology appraisal guidanceTBC
Perioperative care in adultsQuality standard
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]Technology appraisal guidanceTBC
PillCam COLON 2 for investigation of the colon through direct visualisationDiagnostics guidanceTBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]Technology appraisal guidance
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]Technology appraisal guidanceTBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]Technology appraisal guidanceTBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]Technology appraisal guidanceTBC
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Technology appraisal guidance
Polycystic ovary syndrome: assessment and managementNICE guideline
Psoriasis: assessment and management (CG153)NICE guidelineTBC
Pulmonary artery pressure technologies for remote monitoring of chronic heart failureDiagnostics guidance
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]Technology appraisal guidance
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]Technology appraisal guidanceTBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]Technology appraisal guidance
Rehabilitation for chronic neurological disorders including acquired brain injuryNICE guideline
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356Technology appraisal guidanceTBC
Renal cell carcinoma Pathways Pilot [ID6186]Technology appraisal guidanceTBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]Technology appraisal guidanceTBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All